Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Latest Episode
Previous Episodes
- FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari 25.08.2025
- Latest Clinical Data for First-line Maintenance and R/R Small-Cell Lung Cancer (SCLC) 21.08.2025
- FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands 18.08.2025
- Diagnosis and Treatment of Myelofibrosis with Dr. Raajit Rampal: Testing, Treatment, Supportive care 11.08.2025
- Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC) 07.08.2025
- Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET) 04.08.2025
- Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer 31.07.2025
- Challenging Cases with Relapsed/Refractory FLT3+ Acute Myeloid Leukemia (AML) 28.07.2025
- Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies 24.07.2025
- Challenging Cases with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) 21.07.2025
- How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025 17.07.2025
- How to Treat Early Stage Non-Small Cell Lung Cancer in 2025 10.07.2025
- ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA 04.07.2025
- FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial 27.06.2025
- ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04 20.06.2025
- ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04 14.06.2025
- ASCO 2025 Lung Cancer Highlights: CheckMate 816, ToD, NeoADAURA, IMforte, DeLLphi 304 07.06.2025
- Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer 26.05.2025
- Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib 21.05.2025
- How to treat Small Cell Lung Cancer in 2025 19.05.2025
